Show simple item record

dc.contributor.authorAlpuche Aranda, Celia Mercedes
dc.contributor.authorArias, Cesar A.
dc.contributor.authorEspinal Tejada, Carlos
dc.contributor.authorForde, Corey
dc.contributor.authorPark, Benjamin
dc.contributor.authorRossi, Flavia
dc.contributor.authorThormann, Monica
dc.date.accessioned2020
dc.date.available2020
dc.date.issued2020
dc.identifier.citationAlpuche Aranda CM, Arias CA, Espinal Tejada C, Forde C, Park B, Rossi F et al. Scientific evidence for the control of antimicrobial resistance. Rev Panam Salud Publica. 2020;44:e128 https://doi.org/10.26633/RPSP.2020.128en_US
dc.identifier.issn1680 5348
dc.identifier.urihttps://iris.paho.org/handle/10665.2/53141
dc.description.abstract[Extract]. Antimicrobial resistance (AMR) is one of the greatest global threats to human health. It is estimated that by 2050, AMR will lead to approximately 10 million annual deaths worldwide. Considering the impact of AMR on reproductive capacity and food production, in addition to its direct effect on infected people, the world's population could drop by between 11 and 444 million inhabitants by 2050 if AMR control is not achieved. As migrations and shared economies lead to the transmission of resistant bacteria across borders, the impacts of AMR become regionally significant. In the United States, methicillin-resistant Staphylococcus aureus caused 10 600 deaths in 2017. In Latin American and Caribbean countries, information is available from studies conducted in hospitals and other health facilities on the prevalence of antimicrobial-resistant pathogens. In many hospitals in Mexico, Peru, and Colombia, for example, resistance to third-generation cephalosporins and fluoroquinolones in Escherichia coli isolates is reaching almost 60%. Moreover, the dynamics of colonization and infection of multidrug-resistant organisms (such as carbapenemaseproducing Klebsiella pneumoniae) are unique in endemic areas of Latin America, favoring spread and dissemination. [...]en_US
dc.language.isoenen_US
dc.relation.ispartofseriesRev Panam Salud Pública;44, dic. 2020
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 IGO*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/igo/*
dc.subjectDrug Resistance, Microbialen_US
dc.subjectDrug Resistanceen_US
dc.subjectEvidence-Based Medicineen_US
dc.subjectEvidence-Informed Policyen_US
dc.subjectEscherichia colien_US
dc.subjectKlebsiella pneumoniaeen_US
dc.titleScientific evidence for the control of antimicrobial resistanceen_US
dc.typeJournal articlesen_US
dc.rights.holderPan American Health Organizationen_US
paho.articletypeEditorialsen_US
paho.isfeatured0en_US
dc.identifier.doihttps://doi.org/10.26633/RPSP.2020.128
paho.source.centercodeUS1.1en_US
dc.relation.ispartofjournalRevista Panamericana de Salud Públicaes_ES
dc.relation.ispartofjournalPan American Journal of Public Health


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 IGO
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-NoDerivs 3.0 IGO